PCN72 ECONOMIC EVALUATION OF SUNITINIB VS. INTERFERON-A AND BEVACIZUMAB INTERFERON-A IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (CCRM) - BRAZILIAN PRIVATE HEALTH SYSTEM PERSPECTIVE
May 1, 2010, 00:00 AM
10.1016/S1098-3015(10)72161-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)72161-6/fulltext
Section Title :
Section Order :
742
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72161-6&doi=10.1016/S1098-3015(10)72161-6